Compare Ascendis Pharma A/S (ASND) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Tencent Music Entertainment Group - ADR — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Tencent Music Entertainment Group - ADR trades at $8.85 (market cap $14.63B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 2.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TME | |
|---|---|---|
Market Cap | $17.74B | $14.63B |
Sector | Health | Media |
52-Week High | $277.18 | $26.36 |
52-Week Low | $163.32 | $8.16 |
Enterprise Value | $18.11B | $11.41B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TME trades at $8.88, up 0.34% today, with a bullish technical signal despite recent earnings misses. The stock shows strong fundamentals with a P/E of 10.63 and net income margin of 26.48% for 2025. Revenue grew to $32.90B in 2025, though Q2 2026 EPS is expected at $0.24. Analyst consensus is mixed with a $14.00 price target. Recent news highlights strategic moves like the Ximalaya acquisition and partnerships, though competition remains a concern.
The outlook for TME is cautiously optimistic with solid profitability and valuation support, but near-term growth faces headwinds from competition and AI-related challenges. Investors should weigh the attractive margins against execution risks and market sentiment shifts for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
